Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud
German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of...
Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients
US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase...
MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food...
AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for...
TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion
China-based TowardPi (Beijing) Medical Technology Ltd, a leading ophthalmology equipment R&D company, has reportedly secured...
WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...
Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...
AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment
UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for...
Huihe Healthcare’s K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment
Shanghai-based Huihe Healthcare, a developer of structural heart disease intervention medical devices, announced receiving marketing...
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...
Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...
Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban
US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued...
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...
Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced receiving another indication approval from the...
IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture
China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a...
Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced receiving Orphan Drug Designation (ODD) from Japan’s...
Shenzhen GeneMind Biosciences Partners with Precisiongenes for Molecular Diagnostic Innovation
China-based gene sequencer specialist Shenzhen GeneMind Biosciences Co., Ltd. has formed a partnership with compatriot...
Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development
Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-4029 in Acute Ischemic Stroke
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approval from the...